Adult Solid Neoplasm Clinical Trial
Official title:
Calibrated Methods for Quantitative PET/CT Imaging Phase II
This pilot study tests the pocket phantom tool in improving the accuracy of quantitative positron emission tomography/computed tomography (PET/CT) imaging of patients with solid tumors. The pocket phantom tool may help test the accuracy of the PET/CT scanner and indicate whether adjustments need to be made to get consistent information.
PRIMARY OBJECTIVES:
I. Optimize the pocket phantom source design and the bias estimation algorithm: determine the
tolerances and variations in the source sphere geometry and radioactive filing process;
evaluate the need for higher-activity sources in the presence of increased attenuation (i.e.
thicker patients); optimize CT contrast levels for source boundary detection and localization
from CT images; evaluate the robustness for use with different scanner parameters (e.g. CT
slice thicknesses); modify bias estimation algorithm as needed to take into account changes.
II. Develop automated and robust ID pocket phantom processing and web-based software as a
service (SAS) analysis tools: automate initial identification of approximate location of the
pocket phantom; add automated DICOM analysis for web-based SAS analysis tools for imaging
sites.
III. Conduct phantom studies at multiple imaging centers to evaluate the performance with
different imaging protocols, scanners, and reconstruction methods. Also test at multiple time
points over 6-9 months to assess longitudinal stability.
IV. Conduct a comparative study with patients (at University of Washington [UW]) at multiple
time points over 6-12 months to evaluate the performance of the pocket phantom in oncology
patient imaging compared with current clinical practice.
OUTLINE:
Patients undergo a PET/CT scan as part of their standard clinical care. While still
positioned for the clinical scan, patients undergo additional research PET/CT scans in a
smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single
bed position CT scan for attenuation correction (CTAC).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01971489 -
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01093092 -
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT01218620 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00535119 -
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
|
Phase 1 | |
| Completed |
NCT00070252 -
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02107443 -
Improving Communication in Older Cancer Patients and Their Caregivers
|
N/A | |
| Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
| Completed |
NCT01061749 -
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00410553 -
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT00499135 -
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01625156 -
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01154426 -
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02116777 -
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00878163 -
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
|
Phase 1 | |
| Withdrawn |
NCT02627430 -
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT01548482 -
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Active, not recruiting |
NCT01375829 -
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Completed |
NCT00217373 -
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
|
Phase 1 | |
| Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 |